Clinical Trial Update: Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I) [Phase 3]

View source ↗

Summary

Phase 3 trial update on inhaled CMS for non-cystic fibrosis bronchiectasis with chronic Pseudomonas aeruginosa infection assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-cystic Fibrosis Bronchiectasis

Drugs mentioned

• CMS

Snippet

Sponsor: Zambon SpA | Conditions: Non Cystic Fibrosis Bronchiectasis | Phase 3 | Status: COMPLETED | Results posted: 2023-11-15